October - December 2023, Volume 19, Issue 4

Bal AZ, Bal U, Akdogan M, Sezer S

The Effect of Paricalcitol and Calcitriol with or without Calcimimetics on Pulse Wave Velocity and Serum Levels for Parathyroid Hormone, Calcium and Phosphorus in Maintenance Hemodialysis Patients

Acta Endo (Buc) 2023, 19 (4): 480-486
doi: 10.4183/aeb.2023.480

Context. Different vitamin D analogs might have advantages over calcitriol. Objective. To evaluate the effects of paricalcitol vs. calcitriol based vitamin D receptor activators on calcium-phosphate metabolism and pulse wave velocity in hemodialysis patients. Design. Observational, cross-sectional and 1 year follow-up study. Subjects and Methods. 181 hemodialysis patients were enrolled in this study as divided in to 5 groups based on vitamin D therapy. Baseline and 12th month data on blood biochemistry, pulse wave velocity and cumulative dose of treatments were compared in each study group as well as in overall paricalcitol vs. calcitriol-based treatment groups. Results. From baseline to 12th month, significant improvement in pulse wave velocity and parathyroid hormone was shown in paricalcitol-based treatment group without a significant change in calcium, phosphate, alkaline phosphatase. A significant increase in pulse wave velocity, serum phosphate levels, calcium x phosphate product and serum alkaline phosphatase levels were noted in calcitriolbased treatment group with no significant change in serum calcium and parathyroid hormone levels. Conclusion. Our findings revealed superiority of paricalcitol than calcitriol based vitamin D receptor activator therapy in terms of serum phosphate levels, CaxP product, dose requirement for vitamin D and the control of pulse wave velocity.

Keywords: hemodialysis, calcitriol, paricalcitol, pulse wavw velocity.

Correspondence: Ayse Zeynep Bal, MD, Ankara Training and Research Hospital - Nephrology, Hacettepe, Ulucanlar Cd. No:89, 06230 Altindag/Ankara, Turkey, E-mail: zeynepberki@yahoo.com